WARF: P170010US02

  • Patent applied for.

Analogs of Diptoindonesin G for Breast Cancer Drug Development


Wei Xu, Weiping Tang, Jitian Liu, Jill Kolesar

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a novel set of compounds that have been shown to inhibit tumor growth in animal studies.
OVERVIEWThe natural product diptoindonesin G (Dip G) was first isolated in 2009 from the tree bark of Hopea mengarawan. It has shown antiproliferation effects in murine leukemia as well as immunosuppressant activity. Recently, it was reported to promote degradation of estrogen receptor alpha (ERα) while stabilizing ERβ, a tumor suppressor in breast cancer. Importantly, Dip G, by taking a different mechanism from the existing Selective Estrogen Receptor Degrader (SERDs), significantly decreases ERα mutant protein levels found in recurrent, metastatic breast cancer.
THE INVENTIONUW–Madison researchers have synthesized analogs of Dip G that have shown a greater ability than the parent molecule to decrease ERα expression and stabilize ERβ in cultured breast cancer cells. The compounds are active for ameliorating, attenuating and halting the growth/metastasis of breast cancers.
  • Novel compounds for development into breast cancer pharmaceuticals
  • Novel compounds for development in treating endocrine resistant breast cancer harboring ERα mutations
  • Promising toxicity and efficacy data
  • Provides a drug development opportunity in surging market space
  • Innovative licensing and/or development terms may be available.
STAGE OF DEVELOPMENTThese compounds have been shown to degrade mutant ERα that are resistant to Faslodex and Tamoxifen in cell culture model. They also have been shown to shrink breast cancer tumors in a murine model of human breast cancer.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or (608) 265-9861.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.